IHC and RNA sequencing analyses suggested that tumor stability or response following combination treatment was associated with baseline immune-inflamed gene expression patterns similar to the IFN-γ signature associated with response to the PD-1 inhibitor, pembrolizumab.30 In patients who received single-agent ieramilimab treatment, baseline T-cell inflamed signatures tended to be higher in tumor samples from those who exhibited SD (online supplemental figure A4C, online only). The gene discussed is PDCD1; the disease is neoplasm.